JP2021176834A - Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof - Google Patents
Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof Download PDFInfo
- Publication number
- JP2021176834A JP2021176834A JP2021049269A JP2021049269A JP2021176834A JP 2021176834 A JP2021176834 A JP 2021176834A JP 2021049269 A JP2021049269 A JP 2021049269A JP 2021049269 A JP2021049269 A JP 2021049269A JP 2021176834 A JP2021176834 A JP 2021176834A
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- salt composition
- magnesium sulfate
- magnesium chloride
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 20
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 title claims abstract description 17
- 159000000003 magnesium salts Chemical class 0.000 title claims abstract description 15
- 229910001629 magnesium chloride Inorganic materials 0.000 title claims abstract description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 title claims abstract description 8
- 235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 239000007901 soft capsule Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 abstract description 5
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 abstract description 5
- 229960002337 magnesium chloride Drugs 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 abstract description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000013535 sea water Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000002310 Achlorhydria Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229910052609 olivine Inorganic materials 0.000 description 1
- 239000010450 olivine Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、人の病気を治療する為又は殺菌剤としての塩化マグネシウム１，０に対し硫酸マグネシウムの０．６３５を中心として０．２〜０．９の比率範囲に混合した組成物及びその製造方法に関する。INDUSTRIAL APPLICABILITY The present invention is a composition and its production in which 0.635 of magnesium sulfate is mixed in a ratio range of 0.2 to 0.9 with respect to 1,0 of magnesium chloride as a bactericidal agent or for treating human illness. Regarding the method.
海水中には、塩化ナトリウムの他に塩化マグネシウム塩と硫酸マグネシウム塩が組成物として含まれているが、従来は組成物のそれぞれを単剤として研究して来た。In addition to sodium chloride, magnesium chloride salt and magnesium sulfate salt are contained in seawater as compositions, but conventionally, each of the compositions has been studied as a single agent.
しかしながら、発明者は、組成物そのものが不思議な効果を有する事を発見した。港湾中の突堤上に海水がかかっているが、乾燥しても塩類が全く見当たらないこと。また広い海水浴場の乾いた砂浜に塩類が全く見られないこと。等々However, the inventor has discovered that the composition itself has a mysterious effect. Seawater is splashing on the jetty in the harbor, but no salt is found even when it dries. Also, no salt can be seen on the dry sandy beaches of the large beaches. and so on
又、ウイルスが、武漢の方から雨に乗って香川県を渡り兵庫県及び日本全国に降っているが、淡路島、小豆島、佐渡ヶ島には感染者が出ていない。遠く離れた太平洋の島国にもウイルスの雨が降っているが、感染者が居ない。In addition, the virus has spread from Wuhan across Kagawa prefecture to Hyogo prefecture and all over Japan, but no infected person has appeared on Awaji Island, Shodoshima, and Sado Island. It is raining the virus in the remote Pacific island nations, but no one is infected.
これ等のことは、海水中の２種類のマグネシュウム塩組成物が常識では全く考えられない比率に存在することが原因と見ることができる。また、海水は苦くもなく、多量に飲んでも下痢をしない生理作用でも単剤と変化している。These can be attributed to the presence of two types of magnesium salt compositions in seawater in a ratio that is completely unthinkable in common sense. In addition, seawater is not bitter, and even if it is drunk in large amounts, it does not cause diarrhea, and its physiological action is different from that of a single agent.
調査したところ、本発明のマグネシウム塩組成物に関連する先行技術文献は存在しなかった。Upon investigation, there was no prior art document related to the magnesium salt composition of the present invention.
マグネシュウム塩は単剤及び後から単剤を混合して殺菌効果の相乗効果を期待した文献は多々あるが、漫然と混合しただけでは著しい効果は判明されず、結局のところ、塩化マグネシウムは「食品添加物のニガリ」であり、硫酸マグネシウムは「医薬品の下剤」として認められているに過ぎない。 There are many documents that expect a synergistic effect of bactericidal effect by mixing a single agent and a single agent later, but magnesium chloride is "food additive" after all. Magnesium sulphate is only recognized as a "laxative of pharmaceuticals".
本発明は、マグネシウム塩組成物を、人間の常識では考えられない海水中と同様の比率に製造し、それを服用して、治療試験を行なった。その結果、人の病気を治療する著しい効果を確かめ、また製造方法を提供するものである。In the present invention, a magnesium salt composition was produced in a ratio similar to that in seawater, which is unthinkable in human common sense, and the magnesium salt composition was taken to carry out a therapeutic test. As a result, it confirms a remarkable effect of treating a human disease and provides a manufacturing method.
本発明の治療試験には、市販薬の単剤を用いて組成物を製造し、検体として用いた。
水１０００ｍｌ中に塩化マグネシウム六水和物７，０ｇと無水硫酸マグネシウム２，１ｇを溶解させて、海水中の濃度と同様に製造して用いた。この場合、塩化マグネシウムと硫酸マグネシウムの比は１，０：０，６３５となり、海水中の濃度と同様である。In the therapeutic test of the present invention, a composition was produced using a single agent of an over-the-counter drug and used as a sample.
7.0 g of magnesium chloride hexahydrate and 2.1 g of anhydrous magnesium sulfate were dissolved in 1000 ml of water to prepare and use the same concentration as in seawater. In this case, the ratio of magnesium chloride to magnesium sulfate is 1,0: 0,635, which is the same as the concentration in seawater.
被験者は発明者本人（９２歳男性）が偶々胃腸薬のＨ２ブロッカー（ガスター２０）を飲み過ぎて「胃酸が出ない無酸症」になり背中に鈍痛を感じ、ＣＥＡは９，６となり、喉に痰が出て腸間膜内の炎症を示すウイルス性の風邪の症状が出た。風邪薬や希塩酸の服用では回復しなかったので、前記マグネシウム塩溶液を服用した。The subject was a 92-year-old man who accidentally took too much gastrointestinal drug H 2 blocker (Gaster 20) and became "achlorhydria without gastric acid" and felt dull pain in his back, and CEA became 9.6. I had a viral cold with sputum in my throat and inflammation in the mesentery. The magnesium salt solution was taken because it did not recover after taking a cold medicine or dilute hydrochloric acid.
前記の液を食間に１日３回、１回当たり３０ｍｌを２８日間服用した。 The above solution was taken 3 times a day between meals at 30 ml each time for 28 days.
その結果、背中の鈍痛が消え、微熱は下がり、咳、痰など風邪の症状は完全に消失し、更に大腸の動きが良くなり、便秘が解消し、胃下垂が正常になった。意外にも補聴器の聞こえが良くなり、またドライアイ気味の眼が正常になった。As a result, the dull pain in the back disappeared, the low-grade fever decreased, the symptoms of cold such as cough and sputum completely disappeared, the movement of the large intestine improved, constipation disappeared, and gastroptosis became normal. Surprisingly, my hearing aids were better heard and my dry-eye eyes became normal.
この事から、聴覚神経及び視覚神経を回復させる機能が認められた。更には味覚神経及び嗅覚神経をも回復させる機能があると考えられる。From this, the function of recovering the auditory nerve and the visual nerve was recognized. Furthermore, it is considered to have a function of recovering the taste nerve and the sense of smell nerve.
別に上記水溶液を増量し６０ｍｌ服用して歩いていると、突然ベタ足が大股歩きになり、踵から踏み出す若者の歩き方になったので、驚く事に神経と筋肉を弛緩させる作用があると思われた。Separately, when I increased the amount of the above aqueous solution and took 60 ml while walking, my solid legs suddenly became a stride, and it became a way for young people to step out of the heel, so surprisingly it has the effect of relaxing nerves and muscles. It seemed.
従って、パーキンソン病、ＡＬＳなど難病にも効果が有り、正に神が人類に対し海水中に用意された万能薬と拝察している。Therefore, it is effective against intractable diseases such as Parkinson's disease and ALS, and God worships human beings as a panacea prepared in seawater.
また、以前に肺のＣＴ検査で、嚢胞が多発し、長期喫煙による肺胞破壊と消失が見られると、診察された。ところが、最近のレントゲン撮影では、全体が黒くなり完治したので、肺の重篤な病気の予防になると思われる。In addition, it was previously diagnosed that CT examination of the lungs showed frequent occurrence of cysts and alveolar destruction and disappearance due to long-term smoking. However, in recent X-rays, the whole body turned black and healed completely, which seems to prevent serious lung disease.
更に、湿気のあるところに保管していた革靴にカビが生えたので、上記水溶液を塗布したところ、アルコールでは再発生したが、この液では全くカビが生えず、殺菌作用を観察した。Furthermore, since mold grew on the leather shoes stored in a damp place, when the above aqueous solution was applied, it regenerated with alcohol, but no mold grew with this solution, and a bactericidal action was observed.
本発明のマグネシウム塩組成物を医薬品として製造するには、原料として市販品を使うことが出来る。市販品を使って次の２例で製造できる。▲１▼及び▲２▼共にＭｇＣｌ２：ＭｇＳＯ４は、１，０：０．６３５である。
▲１▼ 塩化マグネシウム六水和物：２１０，００ｍｇ
無水硫酸マグネシウム ：６２，４９ｍｇ 計２７２，４９ｍｇの水溶液を適宜ゲル化して、３００〜４００ｍｇの楕円形ソフトカプセルにする。１カプセルは上記試験液の３０ｍｌに相当する。
▲２▼ 塩化マグネシウム六水和物：２１０，００ｍｇ
硫酸マグネシウム七水和物：１２７，９６ｍｇ 計３３７，９６ｍｇの水溶液を適宜ゲル化して、４００〜５００ｍｇの楕円形ソフトカプセルにする。１カプセルは上記試験液の３０ｍｌに相当する。In order to produce the magnesium salt composition of the present invention as a pharmaceutical product, a commercially available product can be used as a raw material. It can be manufactured in the following two examples using a commercially available product. In both (1) and (2), MgCl 2 : sulfonyl 4 is 1,0: 0.635.
(1) Magnesium chloride hexahydrate: 210,000 mg
Anhydrous magnesium sulfate: 62,49 mg A total of 272,49 mg of aqueous solution is appropriately gelled to make 300 to 400 mg of oval soft capsules. One capsule corresponds to 30 ml of the above test solution.
(2) Magnesium chloride hexahydrate: 210,000 mg
Magnesium sulfate heptahydrate: 127,96 mg A total of 337,96 mg of aqueous solution is appropriately gelled to make 400 to 500 mg of oval soft capsules. One capsule corresponds to 30 ml of the above test solution.
子供に対しては、上記の半量を、より小さな適当なソフトカプセルにすれば良い。For children, half of the above can be made into smaller suitable soft capsules.
錠剤、顆粒剤、粉剤は高濃度組成物を噴霧乾燥して原体とするか、或いは乾燥添加物を加えて製造出来るが、無水の状態で効力が、同等か否か試験する必要があるので、当分の間避ける。Tablets, granules, and powders can be produced by spray-drying a high-concentration composition to prepare the drug substance, or by adding a drying additive, but it is necessary to test whether the efficacy is equivalent in an anhydrous state. , Avoid for the time being.
自然に存在するマグネシウム塩組成物の有効例として、三重県山奥の湧水が美味しくて、腐らない、と地元の人が発言している。As an effective example of a naturally occurring magnesium salt composition, locals say that the spring water in the mountains of Mie Prefecture is delicious and does not rot.
富山県の山奥の湧水が、美味しくて、料理に使用し、また麓から来て湯治に１ヶ月通って膠原病を治した、との発言から、浴湯及び茶飲み話に飲んだ茶のマグネシウム塩組成物の効果と思われる。
これ等の山地に含まれる橄欖石等の、マグネシュウムは、全て組成物の形で存在するのであろう。The spring water in the mountains of Toyama Prefecture was delicious and used for cooking, and from the statement that he came from the foot of the mountain and went to a hot spring for a month to cure collagen disease, the magnesium salt of the tea that he drank in the bath and tea drinking talk. It seems to be the effect of the composition.
All of the magnesium, such as olivine contained in these mountains, may exist in the form of a composition.
コロナウイルスの雨に対してもマグネシウム塩組成物が有効で、各県の感染者数を春から冬まで調べているが、秋田県や鳥取県は、地形が同じく少ない。岩手県は海水浴場が多く、感染者は気温が高いと少なく気温が低い冬に多くなる。秋田県や鳥取県も同様の傾向である。この事からマグネシウム塩組成物は揮発性があり、冷温になると、それが低下すると、考えられる。The magnesium salt composition is also effective against the rain of coronavirus, and the number of infected people in each prefecture is investigated from spring to winter, but the topography of Akita and Tottori prefectures is also small. There are many beaches in Iwate prefecture, and the number of infected people is low when the temperature is high and increases in winter when the temperature is low. Akita and Tottori prefectures have the same tendency. From this, it is considered that the magnesium salt composition is volatile and decreases when it becomes cold.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049269A JP2021176834A (en) | 2021-01-29 | 2021-01-29 | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049269A JP2021176834A (en) | 2021-01-29 | 2021-01-29 | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021176834A true JP2021176834A (en) | 2021-11-11 |
Family
ID=78409234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049269A Pending JP2021176834A (en) | 2021-01-29 | 2021-01-29 | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021176834A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533047A (en) * | 2001-06-07 | 2005-11-04 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for prevention and treatment of after ulcers and herpes simplex lesions |
| JP2007015983A (en) * | 2005-07-08 | 2007-01-25 | Noevir Co Ltd | Agent for controlling balance of ecosystem of indigenous bacterium in skin |
| JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
| JP2009051757A (en) * | 2007-08-24 | 2009-03-12 | Isao Moriya | Method for utilizing magnesium chloride for disease of creature such as cow, chicken and pig |
| US7687078B1 (en) * | 2005-10-05 | 2010-03-30 | Scott Cordray | Method of treatment |
| JP2011012059A (en) * | 2009-07-01 | 2011-01-20 | Rohm & Haas Co | Microbicidal composition |
| JP2011016736A (en) * | 2009-07-07 | 2011-01-27 | Lion Corp | Oral liquid composition |
| CN103830271A (en) * | 2014-02-22 | 2014-06-04 | 武汉药谷生物工程有限公司 | Disinfectant composition and application thereof |
-
2021
- 2021-01-29 JP JP2021049269A patent/JP2021176834A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533047A (en) * | 2001-06-07 | 2005-11-04 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for prevention and treatment of after ulcers and herpes simplex lesions |
| JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
| JP2007015983A (en) * | 2005-07-08 | 2007-01-25 | Noevir Co Ltd | Agent for controlling balance of ecosystem of indigenous bacterium in skin |
| US7687078B1 (en) * | 2005-10-05 | 2010-03-30 | Scott Cordray | Method of treatment |
| JP2009051757A (en) * | 2007-08-24 | 2009-03-12 | Isao Moriya | Method for utilizing magnesium chloride for disease of creature such as cow, chicken and pig |
| JP2011012059A (en) * | 2009-07-01 | 2011-01-20 | Rohm & Haas Co | Microbicidal composition |
| JP2011016736A (en) * | 2009-07-07 | 2011-01-27 | Lion Corp | Oral liquid composition |
| CN103830271A (en) * | 2014-02-22 | 2014-06-04 | 武汉药谷生物工程有限公司 | Disinfectant composition and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| BULL. SOC. SEA WATER SCI., JPN, vol. 69, JPN6021030471, 2015, pages 31 - 35, ISSN: 0004722817 * |
| JOURNAL OF NEUROTRAUMA, vol. 15(3), JPN6021030470, 1998, pages 183 - 189, ISSN: 0004722818 * |
| MAGNESIUM RESEARCH, vol. 18(3), JPN6021030468, 2005, pages 187 - 192, ISSN: 0004722819 * |
| MAGNESIUM RESEARCH, vol. 8(2), JPN6021030467, 1995, pages 127 - 135, ISSN: 0004570423 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Coxe | Ethnobotany of the zuni Indians | |
| EP2222314B1 (en) | Uses and means for otaining bronchorelaxation | |
| AU2009266076B2 (en) | Antiallergic marine biopolymers | |
| JP2014500246A5 (en) | ||
| CN104585766A (en) | Composition as well as preparation method and application thereof | |
| US20170080024A1 (en) | Effervescent gargle tablet and method of using same | |
| CN106562966B (en) | Purposes of the compound in anti-posttraumatic stress disorder | |
| TW200930385A (en) | Composition with active ingredient combination for the treatment of constipation | |
| CN102488681A (en) | Ibuprofen diphenhydramine orally disintegrating tablet and preparation method thereof | |
| JP2021176834A (en) | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof | |
| US20130209581A1 (en) | Iodinated activated charcoal for treating symptoms of depression | |
| JP6108635B2 (en) | Rosuvastatin-containing intraoral quick disintegrating tablets | |
| JP4904795B2 (en) | Fatigue improver composition | |
| JP5070047B2 (en) | Gastrointestinal composition | |
| US10383824B2 (en) | Solid beverage for conditioning yin deficiency constitution and method for producing the same | |
| JP2023133314A (en) | Combined compound consisting of magnesium chloride and magnesium sulfate | |
| WO2016074117A1 (en) | Pharmaceutical composition for treating deficiency of kidney and preparation method therefor | |
| CN105456215A (en) | Osteon myospalacem baileyi compound extract tablet with function of treating arthritis and preparing method | |
| JP6864964B2 (en) | Oral sleep improver | |
| JP2021020891A (en) | Magnesium salt composition and production method thereof | |
| RU2619736C2 (en) | Capsules for complex treatment of urinary system diseases | |
| WO2013080271A1 (en) | Analgesic | |
| WO2012177212A1 (en) | Activated carbon and iodine salts for treating depression | |
| JP2014227366A (en) | Compression-molding formulation | |
| JP2021187858A (en) | Pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220308 |